Pharma BD Deal Intelligence

Teva Pharmaceutical Industries Ltd. / Emalex Biosciences, Inc.

2026 · Acquisition/Merger · $900M · Complete

Announcement Sentiment

Strongly positive

Teva will acquire Emalex Biosciences for $700M cash upfront plus up to $200M commercial milestones and net sales royalties to add NDA-ready ecopipam (first-in-class D1 antagonist) for pediatric Tourette syndrome to its neuroscience pipeline; NDA submission expected 2H 2026.

Key facts

Announced Apr 29, 2026
Closed Jun 10, 2026
Deal value $900M
Deal type Acquisition/Merger
Therapeutic area Pediatric Tourette syndrome
Indications Pediatric Tourette syndrome
Key assets Ecopipam (selective dopamine D1 receptor antagonist, NDA-ready)
Mechanism First-in-class selective dopamine D1 receptor antagonist addressing D1 hypersensitivity underlying tic and compulsive behaviors

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals